This activity is expired and is no longer available for CME credit.


Biosimilars and Their Use in Immune-mediated Inflammatory Diseases: Implications for Practice

Author(s)/Faculty: Shubha Bhat, PharmD, MS, BCACP; Francis A. Farraye, MD, MSc; Jonathan Kay, MD
Release Date: 3/31/2020Expiration Date: 3/30/2021
Credit Type: CMENumber of Credits: 0
Content Type: VideoProvider:
Biologic therapy is an effective treatment for a range of immune-mediated inflammatory diseases (IMIDs), including rheumatoid arthritis, psoriasis, and inflammatory bowel diseases. However, due to the high costs of biologics, considerable differences in their utilization exist worldwide. Biosimilars are highly similar but not identical to FDA-approved reference biologic compounds, and no meaningful differences have been found in their quality, safety, or efficacy. Although biosimilars have been approved for use in the United States since 2015, providers continue to lack the knowledge and competence regarding their definition, regulation, and use in patients with IMIDs. In this CME activity, expert faculty will describe the similarities and differences between biosimilars and reference biologic compounds as well as examine the efficacy of biosimilars in the treatment of patients with IMIDs. Participants will gain an understanding of the benefits and limitations of biosimilars, how they may fit into existing treatment algorithms, as well as the potential clinical and financial barriers regarding their use. Participants will also learn how to discuss biosimilars with patients as well as other members of the multidisciplinary team to improve their knowledge and shared decision-making.